We conducted studies with mice, rats, and monkeys which demonstrated the ability of glucan to induce either nonspecific or specific enhancement of host resistance to infectious diseases. Intravenous pretreatment of mice with glucan significantly enhanced the survival of mice challenged with either Venezuelan equine encephalomyelitis (VEE) virus or Rift Valley fever virus. Pretreatment was beneficial when initiated 3 days before challenge with VEE virus and 7 days before challenge with Rift Valley fever virus. Treatment of mice after VEE challenge did not increase their survival compared with controls. Glucan pretreatment of rats provided increased resistance to both intraperitoneal and low-dose aerosol challenges with virulent Francisella tularensis when the glucan was given intravenously, but not when it was administered intranasally. In contrast, intranasal glucan pretreatment enhanced the survival of mice when they were challenged by aerosol with Pseudomonas pseudomallei, whereas intravenous glucan pretreatment did not increase survival. Mice given glucan combined with a marginally immunogenic dose of VEE vaccine were more resistant to homologous virus challenge than were mice given either Freund complete adjuvant plus vaccine or vaccine alone. Similarly, both primary and secondary VEE antibody titers in cynomolgus monkeys given glucan with VEE vaccine were significantly greater than titers in vaccine controls.
The importance of the reticuloendothelial system and its primary component, macrophages, in mediating host resistance to infectious diseases was recognized some time ago. To paraphrase Mims (25) , macrophages are literally in a position to control the susceptibility of animals to infectious diseases, since they monitor the main body compartments and may control the entry of infectious microbes to target organs. Numerous investigators have demonstrated the nonspecific (i.e., not immune-mediated) ability of macrophages to influence host susceptibility or lack thereof to a number of infectious processes (1, 14, 15, 18, 23, 27, 33 Challenge bacteria. Virulent Francisella tularensis strain SCHU S4, which was used for aerosol and i.p. challenges, was prepared and stored at -600C (12) . The aerosol challenge dose was calculated on the basis of the concentration of the organism per liter of aerosol, the duration of exposure, and the tidal volume of the animal (20) .
Pseudomonaspseudomallei ATCC 23343 was used. Its virulence for mice was enhanced by 20 serial intracranial passages, followed by 5 i.p. passages in mice INFECT. IMMUN. (28) rates, respectively, compared with 0 and 5% survivors in their corresponding controls.
(ii) RVF virus challenge. CD-1 mice were placed into treatment groups of at least 40 mice each. One group was given 5.2 mg (0.1 ml) of glucan per 100 g of body weight iv. on days -7, -4, and -1, and another group was given only saline. Mice were challenged subcutaneously on day 0 with either 100 or 250 plaque-forming units of RVF virus. All mice were observed daily, and survival was determined on day 21. Because there was no difference in survival between the two virus challenge doses, results were pooled (Table 1 ). There was a significant potentiation of resistance to challenge with virulent RVF virus in glucan-treated mice compared with controls. Survival in treated mice was 84%, compared with 50% in controls.
(iii) F. tu enis challenge. Inbred Fischer-344 rats were divided into experimental groups (Table 2) . They were treated with glucan (1 mg/ 100 g of body weight) either i.v. or intrnasally (i.n.) on days -5, -3, and -1. The group treated i.n. was anesthetized with halothane (Fluothane; Ayerst Laboratories, New York, N.Y.) before inoculation of the calculated glucan dose in 0.1 ml. Rats were challenged with virulent F. tudarensis by either i.p. inoculation of l06 cells or exposure to l05 or 103 cells in a small-particle aerosol delivered by a modified Henderson tube (20) . Mortality rates were calculated on day 21 postinfection.
Mortality of untreated rats was 100% after i.p. inoculation and 62% after either high-or lowdose aerosol exposure. In contrast, i.v. pretreatment with glucan significantly increased survival of rats challenged both by the i.p. route and by a low-dose aerosol exposure (Table 2 ). However, glucan given i.n. did not increase survival in animals challenged ip.; i.n. glucan pretreatment b Glucan (5.2 mg/100 g of body weight in 0.1 ml) was given i.v. on days -7, -4, and -1, or 0.1 ml of saline was given iv. on days -2, -1, and 0. Table 3 . Glucan given i.n. significantly increased survival of infected mice compared with controls treated with water i.n. Despite the 40% survival rate in the i.n. watertreated and infected controls, the 85% survival rate in the i.n. glucan-treated group was still highly significant (P < 0.001). 'The decreased survival rate of the group given Freund complete adjuvant was not significantly different than the survival rate of vaccine controls (P < 0.01).
vaccination with 425 mouse i.p. 50% lethal doses of virulent VEE virus and were observed for 21 days for mortality. Mice given glucan plus vaccine were significantly more resistant to homologous virus challenge (Table 4 ) than were mice given either vaccine alone or vaccine emulsified in Freund complete adjuvant. The glucantreated group had 81% survivors, compared with 38% for the vaccine controls.
(ii) VEE serum neutralizing antibody production. This study assessed the ability of glucan, when given in combination with VEE vaccine, to enhance both primary and secondary antibody responses to VEE virus in cynomolgus monkeys. Three groups of four monkeys each were inoculated intramuscularly on day 0 and boosted on day 28 with 0.5 ml of VEE vaccine alone or VEE vaccine combined with either 0.5 or 1.0 mg of glucan per 100 g of body weight. All monkeys were bled at weekly intervals for serum neutralizing antibody determinations.
The geometric mean serum neutralizing antibody titers for all groups of monkeys over an 87-day period are shown in Fig. 3 . The antibody titers in the three groups during the first 21 days post-inoculation were not significantly different. However, on day 28 the titers in monkeys given 1.0 mg of glucan per 100 g of body weight combined with vaccine were significantly (P < 0.05) greater than the titers in the vaccine controls.
After boosting on day 28, the antibody titers in monkeys given 1.0 mg of glucan per 100 g of body weight plus vaccine remained significantly elevated compared with the vaccine controls for at least 52 days. In contrast, the antibody responses of monkeys after two doses of vaccine combined with 0.5 mg of glucan per 100 g of body weight were significantly elevated only on days 42 through 56 compared with the titers in the vaccine controls. On day 87, when the experiment was terminated, the antibody titers of monkeys given two injections of vaccine combined with either 1.0 or 0.5 mg of glucan per 100 g of body weight were 22-fold (1:512) and 3-fold (1:64) higher, respectively, than the titers in the vaccine controls (1:23).
DISCUSSION We utilized glucan to alter nonspecifically the course of several lethal experimental infections in mice and rats. In addition, we demonstrated the ability of glucan to enhance specifically the resistance of mice to homologous virus challenge and to potentiate both primary and secondary antibody responses in nonhuman primates. Since glucan has been shown by others to induce readily both hyperplasia and hyperfunction of the reticuloendothelial system (2, 3, 9, 36) , it is our assumption that this enhanced nonspecific resistance and this specific resistance were due primarily to macrophage-mediated events.
The possible role of glucan-induced interferon as a mediator of the increased nonspecific resistance to both VEE and RVF virus challenges seen in our studies was not examined. Since glucan is now known to be an interferon inducer (Di Luzio, unpublished data), this explanation seems likely. In addition, pretreatment of mice with glucan before challenge with a lethal virus infection may create an environment for a more efficient induction of interferon by the virulent challenge virus. This priming or augmentation of interferon production has been noted by others both in vivo and in vitro, using various synthetic interferon inducers and viruses (13, 32) .
The pathogeneses of both RVF virus and VEE virus infections have a significant macrophage component (19, 24, 25) . The phagocytic cells of the reticuloendothelial system are uniquely situated to provide a functional blockade to virus infection of hepatocytes or other target organs (25, 26, 34) . Indeed, our studies suggest that by enhancing macrophage function with glucan, the reticuloendothelial system is in an as-yet-undefined manner capable of effectively reducing the pathogenicity of VEE and RVF virus infections in mice. An examination of the biochemical and cellular events responsible for this glucan-induced enhanced resistance would be a worthwhile endeavor.
The ability of macrophages to alter the fate of intracellular microorganisms, especially bacteria, has been reported (15, 23) , although the precise mechanisms are not entirely understood. Most studies demonstrating glucan-induced immunopotentiation have dealt only with infectious agents that are primarily opportunistic (e.g., Staphylococcus spp., Candida, sporotrichosis) and with noninfectious neoplastic diseases (7, 8, 10, 22 (35) and specific protective immunity when given as an adjuvant in the abovedescribed studies is most easily explained by glucan enhancement (i.e., macrophage-mediated amplification) of immune induction.
We did not evaluate systemic morphological changes induced in our studies. Obviously, before the use of macrophage stimulants like glucan would be clinically acceptable, additional work (7) would be required to demonstrate that glucan is nonreactogenic and nontoxic and does not induce irreversible systemic morphological changes when given at effective dosage levels.
The true benefit of macrophage stimulants, such as glucan, may reside not only in their adjuvant activitiy, but also in their ability to maintain nonspecific resistance to infectious diseases while a host is temporarily immunosuppressed, as is the case with cancer chemotherapy and radiation injuries.
